353 related articles for article (PubMed ID: 29486338)
1. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial.
Ghazizadeh-Hashemi M; Ghajar A; Shalbafan MR; Ghazizadeh-Hashemi F; Afarideh M; Malekpour F; Ghaleiha A; Ardebili ME; Akhondzadeh S
J Affect Disord; 2018 May; 232():127-133. PubMed ID: 29486338
[TBL] [Abstract][Full Text] [Related]
2. L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial.
Araminia B; Shalbafan M; Mortezaei A; Shirazi E; Ghaffari S; Sahebolzamani E; Mortazavi SH; Shariati B; Ardebili ME; Aqamolaei A; Naderi S; Akhondzadeh S
J Affect Disord; 2020 Apr; 267():131-136. PubMed ID: 32063564
[TBL] [Abstract][Full Text] [Related]
3. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis.
Steels E; Venkatesh R; Steels E; Vitetta G; Vitetta L
Inflammopharmacology; 2019 Jun; 27(3):475-485. PubMed ID: 30927159
[TBL] [Abstract][Full Text] [Related]
4. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
5. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.
Papakostas GI; Fava M; Baer L; Swee MB; Jaeger A; Bobo WV; Shelton RC
Am J Psychiatry; 2015 Dec; 172(12):1251-8. PubMed ID: 26085041
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial.
Sepanjnia K; Modabbernia A; Ashrafi M; Modabbernia MJ; Akhondzadeh S
Neuropsychopharmacology; 2012 Aug; 37(9):2093-100. PubMed ID: 22549115
[TBL] [Abstract][Full Text] [Related]
7. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
8. Riluzole combination therapy for moderate-to-severe major depressive disorder: A randomized, double-blind, placebo-controlled trial.
Salardini E; Zeinoddini A; Mohammadinejad P; Khodaie-Ardakani MR; Zahraei N; Zeinoddini A; Akhondzadeh S
J Psychiatr Res; 2016 Apr; 75():24-30. PubMed ID: 26800392
[TBL] [Abstract][Full Text] [Related]
9. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.
Abbasi SH; Hosseini F; Modabbernia A; Ashrafi M; Akhondzadeh S
J Affect Disord; 2012 Dec; 141(2-3):308-14. PubMed ID: 22516310
[TBL] [Abstract][Full Text] [Related]
10. Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial.
Khalaj M; Saghazadeh A; Shirazi E; Shalbafan MR; Alavi K; Shooshtari MH; Laksari FY; Hosseini M; Mohammadi MR; Akhondzadeh S
J Psychiatr Res; 2018 Aug; 103():104-111. PubMed ID: 29807317
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
[TBL] [Abstract][Full Text] [Related]
12. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tipepidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial.
Hoobehfekr S; Moghaddam HS; Shalbafan M; Hashemi MG; Pirmoradi MM; Sakenian A; Poopak A; Kashefinejad S; Yarahmadi M; Akhondzadeh S
Psychiatry Clin Neurosci; 2021 Feb; 75(2):57-62. PubMed ID: 33247483
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
Lin CH; Lin SH; Jang FL
J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
16. Quetiapine as combination treatment with citalopram in unipolar depression with prominent somatic symptoms: a randomised, double-blind, placebo-controlled pilot study.
Quante A; Regen F; Schindler F; Volkmer K; Severus E; Urbanek C; Luborzewski A; Roepke S; Anghelescu I
Psychiatr Danub; 2013 Sep; 25(3):214-20. PubMed ID: 24048387
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
Fraguas R; da Silva Telles RM; Alves TC; Andrei AM; Rays J; Iosifescu DV; Wajngarten M
Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of citalopram with aspirin for treating major depressive disorder, a double blind randomized placebo controlled clinical trial.
Ghanizadeh A; Hedayati A
Antiinflamm Antiallergy Agents Med Chem; 2014; 13(2):108-11. PubMed ID: 25091820
[TBL] [Abstract][Full Text] [Related]
20. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
